Epigenetic cancer therapy specialist Epizyme Inc. has ended development of its lead product tazemetostat as a monotherapy or in combination with prednisolone for diffuse large B-cell lymphoma, or DLBCL. The company has also pushed back the expected timeline for submitting its US NDA for the drug's first indication of epithelioid sarcoma. And it disappointed investors in offering no clear timeline for the resolution of a partial clinical hold on trials of the drug during its second-quarter investor call.
The termination came after an evaluation of the level of clinical activity in the three DLBCL cohorts of a Phase...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)